Tell us about your biggest trial win from January 2016 to July 2017 and how you achieved the result for your client.
From the client’s perspective, all trials are the “biggest,” and our team approaches every matter that way. For the legal community, the In re Modafinil trial is perhaps most interesting, as this was only the second “reverse payment” case to go to trial since the Actavis decision (my team also tried the first one, In re Nexium).
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
